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Post-transplant lymphoproliferative disorders (PTLD) are a major source of morbidity and mortality in transplantation medicine. They occur in about 5% of solid organ transplant patients and in 1% of haematopoietic stem cell transplant patients (Swerdlow, 2008) , are predominantly of B-cell origin, and most of monomorphic PTLD are diffuse large B-cell lymphomas (DLBCL). Epstein-Barr virus (EBV) association is significantly stronger in post-transplant DLBCL (PT-DLBCL) as compared to DLBCL in immunocompetent (IC-DLBCL) patients (Swerdlow, 2008) .
In recent years, major progress has been accomplished in elucidating the genetic landscape of IC-DLBCL (Pasqualucci & Dalla-Favera, 2015) . In addition to the identification of distinctive mutational patterns among germinal centre B-celllike (GCB) and activated B-cell-like (ABC/non-GC) subtypes, insights into both pathogenetically relevant pathways and potentially targetable mutations have been obtained. The latter range from interference with B-cell receptor-and nuclear factor (NF)-jB signalling (Davis et al, 2010) to influencing of epigenetic regulators (McCabe et al, 2012) .
It is still a matter of debate whether PT-DLBCL constitutes a single homogenous entity or should be divided into biologically relevant subtypes, and this may also have therapeutic implications. As EBV plays a significant pathogenetic role in PTLD, it would be logical to divide PTLD by EBV association. Clinical observations, pathological studies and recent molecular studies substantiate such a strategy (Leblond et al, 1998; Nelson et al, 2000) . Ferreiro et al (2016) aberrations. These findings are confirmed by observations from other groups employing different techniques and approaches (Poirel et al, 2005; Rinaldi et al, 2006 Rinaldi et al, , 2010 . A recent study investigating T-cell and natural killer (NK) cell PTLDs by Next Generation Sequencing (NGS) has shown that this subgroup harbours the same mutations as their counterparts arising in immune competent patients (Margolskee et al, 2016) . There is currently an ongoing debate as to whether PT-DLBCL shows a distinct pattern of genetic changes that would separate them from conventional DLBCL (Tsai & Reshef, 2016 
Material and methods

Cases
The cohort consists of two groups of PTLD samples from the Institute of Pathology, University Hospital Basel, Switzerland (Basel cohort) and from the Department of Cellular and Molecular Pathology, Imperial College NHS Trust Hammersmith Campus, London, United Kingdom (Imperial cohort). The Basel cohort has already been extensively studied at the protein and cytogenetic levels (Menter et al, 2016) and consisted of 16 PT-DLBCLs, 3 polymorphic PTLDs and one case each of lymphomatoid granulomatosis and plasmablastic lymphoma. Imperial tissue samples were provided by the Imperial College Healthcare National Health Service Trust Tissue Bank and consisted of 21 PT-DLBCLs and 6 polymorphic PTLDs. Non-tumour tissue to exclude germline variants was available for 13 (Basel) and 10 (Imperial) cases. The COO subtyping of the PT-DLBCLs had been determined applying the Hans algorithm (staining for CD10, BCL6 and MUM1) (Hans et al, 2004) . All PT-DLBCL cases showed the typical morphology of DLBCLs, i. e. sheets of medium to large sized nucleolated lymphoid cells. None of the cases classified as PT-DLBCLs had a polymorphic infiltrate or any Hodgkin-like cells.
DNA extraction
Genomic DNA (gDNA) was extracted from formalin-fixed and paraffin-embedded (FFPE) tissues with >70% tumour cell content in samples of PT-DLBCL and >30% tumour cell content in samples of polymorphic PTLDs. Each case was evaluated by two haematopathologists in order to confirm the diagnosis and to estimate the tumour cell content. Depending on the distribution of tumour cells, 25 lm-thick tissue rolls were cut or tumour tissue was scratched off from 10 lm-thick unstained sections. For gDNA extraction, the GeneRead DNA FFPE kit (Qiagen, Nussloch, Germany) was used. gDNA yields were quantified by the Qubit high sensitivity DNA assay (Life Technologies, Eugene, OR, USA).
Targeted NGS and data analysis
Library preparation and sequencing of all samples was uniformly performed at the research laboratory of the Institute of Pathology, University Hospital Basel, Switzerland. A customized panel comprising 933 amplicons of 68 genes in 4 primer pools (234 amplicons/pool in average) was used as described previously 2016) . MetaLR score was used to predict functional impact of non-synonymous variants to the encoded protein (Dong et al, 2015) . Criteria used for mutation filtering after variant calling are provided in Supplementary Table SI. For validation purposes, three cases of the PT-DLBCLcohort were sequenced independently for a second time, and they showed concordant results. Also, this NGS-panel has previously been employed in our published studies, and results have been validated by Sanger sequencing . Furthermore, as this panel is currently also employed in the routine diagnostic work-up in Basel, 30 cases with mutations of MYD88, JAK2, BRAF and TP53 initially detected by Sanger sequencing were used for further validation and the NGS panel detected all mutations in this cohort.
Comparative cohort of DLBCLs of immunocompetent patients
A cohort of 76 de novo DLBCLs in immunocompetent (IC) patients was available for comparative analysis Tzankov et al, 2015) (see also www.eahp2016.com/f ileadmin/templates/main/eahp2016/ebook/index.html#/79). All these cases had been processed and analysed in Basel similar to the PTLD samples. Furthermore, DLBCL-specific gene mutational frequencies were obtained from the Catalogue Of Somatic Mutations In Cancer (COSMIC) database (cancer. 
Statistical analysis
All statistical calculations were performed with MS Excel 2013 (Microsoft, Redmond, WA, USA), SPSS 22Á0 (IBM Corp., Armonk, NY, USA) or R statistical package (http:// www.r-project.org/). Statistical significance threshold of P < 0Á05 was assumed in all analyses.
Results
Clinico-pathological characteristics
The PT-DLBCL group of 36 analysable cases consisted of 23 male and 13 female patients, including 28 kidney, five liver, two heart and one haematopoietic stem cell transplanted individuals (see Supplementary Table SII Nine samples of polymorphic PTLD were also a part of this study (see Supplementary Table SII for further details). They represented six male and three female patients. Six and three patients had received kidney and haematopoietic stem cell transplants respectively. Median age at transplantation was 43Á5 years (IQR: 26Á4 years). Median age at diagnosis of PTLD was 43Á7 years (IQR: 23Á6 years). The median interval from time of transplant to time of PTLD diagnosis was 8Á9 years (IQR: 18Á1 years).
Description of the individual clinico-pathological data including COO classification and EBV status can be found in the supplementary files (Supplementary Tables SIII and SIV) .
General observations on mutational profile of PTLDs
Sequencing and data analysis was successful in 20/21 cases of the Basel cohort and in all 27 cases of the Imperial cohort.
A total of 156 mutations in 38 different genes were detected (see also Supplementary Table SV). These comprised 127 missense mutations, 6 insertions/deletions, 22 nonsense mutations and 1 stop-loss mutation. Six PTDLBCLs and 6 polymorphic PTLDs did not show any detectable mutation in the analysed genes. The case of plasmablastic lymphoma and the case of lymphomatoid granulomatosis did not show any detectable mutations and were not included for further analysis. No statistically significant differences regarding mutational frequencies or mutated genes were seen in the two cohorts (Basel and Imperial) and thus they were combined for all analyses.
The median number of mutations per case were 0 (IQR: 1Á5), 3 (IQR: 5) and 4 (IQR: 4) in polymorphic PTLD, PT-DLBCL and IC-DLBCL respectively. The median number of mutated genes per case were 0 (IQR: 1Á5), 2 (IQR: 3) and 4 (IQR: 3) in polymorphic PTLD, PT-DLBCL and IC-DLBCL respectively.
The most commonly mutated genes in the PT-DLBCL were Lysine Methyltransferase 2D (KMT2D) and Tumour Protein p53 (TP53), which were seen in 13 PT-DLBCL each. All TP53 mutations were either protein damaging or nonsense mutations. The mutational frequencies of PT-DLBCL in comparison with IC-DLBCL are shown in Fig 1. Figure 2 shows a mutational heat-map indicating their type and potential damage to encoded proteins.
There were no statistically significant correlations between the numbers of mutations or the number of mutated genes and the interval between transplantation and diagnosis of PTLD; or between early (PTLD within the first year after transplantation) and late (PTLD occurring later than the first year after transplantation) PTLD subsets.
PT-DLBCL differs in its mutational profile from IC-DLBCL
The difference in the number of mutated genes per case and the number of total mutations per case between PT-DLBCL and IC-DLBCL was not statistically significant. There was however, a trend towards fewer mutations in genes related to NF-jB signalling (CARD11, IRF4, MYD88, PIM1, PRDM1, TNFAIP3) in PT-DLBCL as compared to IC-DLBCL (P = 0Á06). TP53 mutations were significantly more frequent in PT-DLBCL than in IC-DLBCL (P = 0Á004; 36Á1% in PT-DLBCL vs. 11Á8% in IC-DLBCL). This was further confirmed on comparison with data from the COSMIC database [P = 0Á005; 36Á1% in PT-DLBCL vs. 19Á4% in DLBCL (COS-MIC database)]. In contrast, PT-DLBCLs lacked Beta2-microglobulin (B2M) and Ataxia Telangiectasia Mutated (ATM) mutations (P = 0Á016 and P = 0Á004, respectively). However, when analysing mutations of genes involved in DNA damage control (TP53 and ATM) as a total sum, there was no difference between PT-DLBCL and IC-DLBCL. Mutations of ATM and TP53 were almost mutually exclusive in IC-DLBCL. Statistically significant differences in mutational frequencies between PT-DLBCL and IC-DLBCL were seen in Caspase Recruiting Domain Family Member 11 (CARD11) (P = 0Á031; 5Á6% in PT-DLBCL vs. 22Á4% in IC-DLBCL) and Suppressor of Cytokine Signalling 1 (SOCS1) genes (P = 0Á006; 5Á6% in PT-DLBCL vs. 27Á6% in IC-DLBCL). Table I gives a summary of the statistically significant differences in mutated genes among PT-DLBCL and IC-DLBCL (Supplementary  Table SVI shows a detailed list of mutations in all genes studied and respective frequencies).
EBV-positive PT-DLBCL differs in its mutational profile from EBV-negative PT-DLBCL All PTLDs were investigated for EBV association using EBV small RNA (EBER) in situ hybridization probe. We defined EBV-positivity as documentation of EBV in at least 10% of tumour cells. However, most EBV + PTLD displayed 100% positivity among tumour cells. EBER was positive in 11/36
T. Menter et al (31%) cases of PT-DLBCLs. EBV + PT-DLBCL had fewer number of mutations per case (P = 0Á024; median 1 vs. 3) and fewer number of mutated genes per case (P = 0Á020; median 1 vs. 3) as compared to EBV -PT-DLBCL. EBV + PT-DLBCL also had fewer number of mutated genes as compared to IC-DLBCL (P = 0Á006; median 1 vs. 4). Furthermore, EBV + PT-DLBCL had fewer mutations in genes within the NF-jB signalling pathway as compared to IC-DLBCLs (P = 0Á044; mean of 0Á19 vs. 0Á69 mutations per case). Although TP53 mutations were less frequent in EBV + PT-DLBCL as compared to EBV -PT-DLBCL (18% and 44% respectively), the difference was not statistically significant (P = 0Á259). EBV -PT-DLBCL had an overall mutational frequency similar to IC-DLBCLs, yet TP53 mutations were more frequent in EBV -PT-DLBCL as compared to IC-DLBCL (P = 0Á001; 44Á0% vs. 11Á8%). As compared to IC-DLBCL, EBV -PT-DLBCLs did not show any difference in frequency of mutations within gene clusters related to NF-jB signalling and epigenetic modifiers.
Nine of 11 EBV + PT-DLBCLs and 9/25 EBV -PT-DLBCLs were of non-GC subtype. EBV + PT-DLBCLs were more likely to be of non-GC subtype (P = 0Á01). EBV association correlated with younger age at transplantation (median age: 35Á4 and 50Á7 years for EBV + and EBV -cases respectively; Spearman correlation coefficients q = 0Á408, P = 0Á017) and with a younger age at diagnosis of PTLD (median age: 47Á8 and 56Á1 years for EBV + and EBV -cases respectively; Spearman correlation coefficients q = 0Á434, P = 0Á008).
COO subsets of PT-DLBCL did not differ in mutational profiles
Although GCB-PT-DLBCLs had fewer mutations per case (median: 2 vs. 3Á5) and fewer mutated genes per case (median: 2 vs. 3Á5) when compared to non-GC PT-DLBCL, the differences were not statistically significant (P = 0Á074 and P = 0Á111 respectively). GCB-PT-DLBCL had fewer number of mutations per case (median: 2 vs. 4) and fewer number of mutated genes per case (median: 2 vs. 4) as compared to GCB-IC-DLBCL (P = 0Á048 and P = 0Á04 respectively). Non-GC-PT-DLBCL showed a higher frequency of mutations in genes related to epigenetic modifiers as compared to non-GC-IC-DLBCLs (median of 1 vs. 0; P = 0Á026). Non-GC-PT-DLBCL also showed a higher frequency of mutation in TP53 as compared to non-GC-IC-DLBCLs (39% vs. 16%; P = 0Á01).
Polymorphic PTLDs have a lower mutation load as compared to PT-DLBCL
Nine polymorphic PTLDs with EBV association were investigated; 6/9 did not show any detectable mutation. Two cases had three mutations each; one case showed one mutation. One mutation each was found in NOTCH1, KRAS, JAK3, TET2 and PTPN1; two mutations were seen in PAX5. The frequency of mutations in polymorphic PTLDs was significantly lower as compared to monomorphic PT-DLBCLs (median: 0 vs. 3; P = 0Á001).
Discussion
This study documented the mutational profile of B-cell PTLD with respect to 68 selected genes that are frequently mutated in DLBCL. This is the largest cohort of B-cell PTLD so far investigated by NGS, although several other studies have addressed gene expression and copy number changes in PTLDs (Morscio et al, 2013; Ferreiro et al, 2016) . We have shown that the mutational landscape of PT-DLBCL in general differs from that of IC-DLBCL. EBV + and EBV -PT-DLBCL display substantial differences in their mutational landscape, strengthening the rationale to separate PT-DLBCL into subgroups based on EBV association, as these might demand different management approaches apart from having different prognoses. Subtyping PT-DLBCL based on EBV association appeared to have more biological relevance than subtyping them based on COO. Obviously, as the numbers are relatively small, our results should be interpreted with some caution. However, our findings are corroborated by findings in other studies that have applied different techniques (Poirel et al, 2005; Rinaldi et al, 2006 Rinaldi et al, , 2010 Morscio et al, 2013; Ferreiro et al, 2016) . In this study we have uncovered several differences between the genetic landscapes of PT-DLBCL and IC-DLBCL. They include:
1 EBV -PT-DLBCL have more frequent TP53 mutations. A similar high frequency of TP53 mutations had been previously documented in a study on primary central nervous system DLBCL (by definition EBV -) (Todorovic Balint et al, 2016). All TP53 mutations seen in our study were damaging or nonsense mutations; hence, they are highly likely to be of pathogenetic significance. Previous studies that investigated PT-DLBCL samples for presence of TP53 mutations had also identified a disproportionately high frequency of TP53 mutations in EBV -PT-DLBCL (Knowles et al, 1995; Greiner et al, 2000; Courville et al, 2016) . While the adverse impact of TP53 mutations on clinical outcome is well documented in DLBCL patients (Xu-Monette et al, 2012) , the prognostic impact of lack of EBV association in PT-DLBCL is still uncertain (Luskin et al, 2015) . In contrast, mutations of ATM, which encodes for a crucial checkpoint kinase, were not seen in the entire PT-DLBCL cohort. In IC-DLBCL, mutations in ATM were common (mutational frequency of 18Á4%), and mutations in TP53 and ATM were almost mutually exclusive. 2 B2M was the other gene in which no mutations were found among PT-DLBCL samples. Expression of B2M is critical for recognition of cells by the adaptive immune system (Peaper & Cresswell, 2008) . Downregulation of B2M is a well-recognized mechanism of immune evasion by lymphomas (Challa-Malladi et al, 2011) . Immune evasion is less likely to be a critical pathogenetic mechanism in PT-DLBCL as they relatively lack tumour-infiltrating T-cells (Morscio et al, 2013) . 3 Lower frequencies of CARD11 and SOCS1 mutations were observed in PT-DLBCL. The differences in the frequencies were more significant when compared to our IC-DLBCL cohort than to the COSMIC database (Forbes et al, 2015) . As SOCS1 is involved in JAK/STAT signalling (Sasaki Table I . Summary of statistically significant differences in the mutational profiles of PT-DLBCL and IC-DLBCL in our study. A detailed list of mutational frequencies can be found in the supplementary files. Mutations 3 (5) 1 (3Á5) 4 (6) 2 (3) 3Á5 (5Á5) 4 (3) 4 (3) 2 (3) n.a.*
Mutated genes per case: Median (IQR)
2 (3) 1 (2Á5) 3 (2) 2 (1Á75) 3Á5 (1Á75) 4 (3) 4 (3) 3 (3) n.a.* al, 1999) , the lack of SOCS1 mutations further corroborates our previous findings that perturbation of JAK/ STAT pathway may not be a common pathogenetic mechanism in PT-DLBCL (Menter et al, 2016) . The lack of CARD11 mutations in PT-DLBCL suggests possible alternate mechanisms for activation of NF-jB signalling in this entity (discussed in more detail in the next paragraph).
ATM
Similar to observations from other groups, we demonstrate distinct genetic differences between EBV + and EBV -PT-DLBCL (Poirel et al, 2005; Rinaldi et al, 2006 Rinaldi et al, , 2010 . The reason why genetic abnormalities are less frequent in EBV + PT-DLBCL is yet to be fully elucidated. We hypothesize that the virus' oncogenic activity substantially contributes to lymphoma development, substituting the need for activating mutations of oncogenes or silencing mutations of tumour suppressors in EBV + PT-DLBCL. The reduced frequency of mutations related to NF-jB signalling in EBV + PT-DLBCL provides further support to our hypothesis. This is substantiated by our previous study, which documented the lack of expression of NF-jB signalling-related proteins in EBV + PT-DLBCL (Menter et al, 2016) . Analogously, investigations on EBV-associated DLBCL of the elderly have also shown lower mutation frequencies in NF-jB pathway-related genes (Gebauer et al, 2015) . EBV infection and subsequent expression of the latent membrane protein (LMP) 1 and LMP2A can activate the NF-jB pathway and substitute the need for mutations in genes involved in aberrant activation of NF-jB pathway (Guasparri et al, 2008; Kieser & Sterz, 2015) . Molecular subtyping of DLBCL into COO subtypes either by gene expression analysis or by immunohistochemistry has prognostic and therapeutic impact, and is recommended by the updated WHO classification of lymphoid neoplasms (Young et al, 2015; Swerdlow et al, 2016) . Although GCB PT-DLBCLs had fewer mutations than non-GC PT-DLBCL, the difference was not statistically significant. Furthermore, we did not observe any statistically significant differences in mutations of specific genes between GCB and non-GC subtypes of PT-DLBCL. We observed a higher frequency of mutations in TP53 and in genes related to epigenetic modifiers on non-GC PT-DLBCL as compared to non-GC IC-DLBCL. Biological and clinical significance of these observations need further analyses.
Mutations in genes involved in epigenetic modification are frequent in DLBCL (Morin et al, 2011; Pasqualucci et al, 2011) and are considered to be early events in lymphomagenesis (Green et al, 2013) . As discussed above, KMT2D was the most commonly mutated gene in both our PT-DLBCL and IC-DLBCL cohorts. Studies on DLBCL and follicular lymphoma had previously identified KMT2D as the most frequently mutated gene among these B cell lymphomas (Morin et al, 2011) . Dubois et al demonstrated that mutations in genes related to epigenetic modification are more frequent in GCB DLBCL than non-GC-DLBCL (Dubois et al, 2016) . We, however, did not observe any significant difference in frequency of KMT2D mutations between GCB and non-GC subsets of our PT-DLBCL cohort.
Limitations of our study include the retrospective nature of the study, some deficiencies in clinical data (the included cases were diagnosed over a long period of time) and limited sample size. Although these limitations pose challenges to subgroup analysis, we believe the differences we have noticed between EBV-positive and EBV-negative subsets of PTLD represent true differences in their mutational biology, as findings from other groups using different techniques corroborate with our findings (Poirel et al, 2005; Rinaldi et al, 2006 Rinaldi et al, , 2010 Morscio et al, 2013; Ferreiro et al, 2016) .
Overall, our results will aid a better understanding of the molecular pathogenesis of PTLD in general and PT-DLBCL in particular and provide new insights into their mutational landscape. They would also possibly provide a better molecular basis for targeted therapy in PTLD patients.
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